-
Mindray Bio-Medical Partners with Nanjing Drum Tower Hospital to Boost Clinical Research
•
Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760), a leading medical equipment provider, has entered into a partnership with Nanjing Drum Tower Hospital, a prestigious and historically significant hospital in China. The collaboration will focus on key medical disciplines of the hospital and involve clinical study cooperation as part of…
-
Qilu Pharmaceutical’s QL1706 Receives NMPA Conditional Approval for Cervical Cancer Treatment
•
Qilu Pharmaceutical, a Chinese pharmaceutical company, has announced that its combination drug QL1706, comprising iparomlimab and tuvonralimab, has received conditional marketing approval from the National Medical Products Administration (NMPA) for the treatment of recurrent or metastatic cervical cancer. QL1706 (PSB205), originally developed by the U.S. biotech Qilu Puget Sound Biotherapeutic…
-
Study Predicts 2025 Medicare Part D Negotiation Candidates, With Novo Nordisk’s Semaglutide Leading the List
•
Researchers in the U.S. have compiled a list of drugs that are anticipated to be part of the Medicare Part D drug price negotiations in 2025. The Center for Medicaid Services (CMS) initiated negotiations for 10 Medicare Part D drugs in August of this year and is projected to release…
-
Dupixent Secures Back-to-Back COPD Approvals from US FDA and China NMPA
•
Regeneron (NASDAQ: REGN), a leading biopharmaceutical company based in the U.S., in collaboration with its French partner Sanofi (NSE: SANOFI), announced on September 27 that Dupixent (dupilumab) has received approvals for the treatment of chronic obstructive pulmonary disorder (COPD) from both the U.S. Food and Drug Administration (FDA) and China’s…
-
AbbVie Submits First BLA for c-Met Targeting ADC Telisotuzumab Vedotin to FDA
•
AbbVie Inc. (NYSE: ABBV), a leading pharmaceutical company in the U.S., has announced the filing of a first Biologics License Application (BLA) for telisotuzumab vedotin (Teliso-V), a first-in-class antibody-drug conjugate (ADC) targeting tumors that overexpress the c-Met protein. The U.S. Food and Drug Administration (FDA) has accepted the filing for…
-
Whittilong Pharma Secures Over RMB 100 Million in Series B Financing for Modified Drug Development
•
Whittilong Pharma, a Shanghai-based modified drug development company backed by Shanghai Healthcare Capital (SHC), has reportedly secured over RMB 100 million in a Series B financing round. The funding was provided by multiple family offices. Established in 2018, Whittilong Pharma specializes in the research and development of a diverse range…
-
HOYA Surgical Optics Expands in China with New Artificial Intraocular Lens Facility
•
HOYA Surgical Optics has established its presence in the Suzhou High-Tech Zone of Jiangsu province, China, with a focus on developing artificial intraocular lenses and their implantation systems to benefit a broader patient base affected by cataracts. HOYA Surgical Optics, a subsidiary of Japan’s Hoya Corporation, holds a leading position…
-
Shanghai Pharmaceuticals Partners with SIBPT to Boost Biopharmaceutical R&D and Translation
•
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has entered into a partnership with the Shanghai Institute for Biomedical and Pharmaceutical Technologies (SIBPT), formerly known as the Shanghai Institute of Planned Parenthood Research (SIPPR). The collaboration aims to enhance collaboration in scientific research and development, achievement translation, team building, and party…
